Today: September 23, 2018, 11:28 pm
  
Business

Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

PR-Inside.com: 2018-03-13 10:03:06

Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

Abzena plc
John Burt, CEO
Campbell Bunce, SVP, Scientific Operations
Min Park, Global Head of Marketing
Joseph Reeds, Marketing Manager
+441223903498
min.park@abzena.com
or
Instinctif Partners
Melanie Toyne Sewell
+442074572020
abzena@instinctif.com

Abzena plc, the life sciences group providing services and technologies to enable the discovery, design, development and manufacture of biopharmaceutical products, has signed an agreement to access a major cell line depository.

The agreement with an unnamed institution will allow Abzena access to cell lines representing multiple different species, tissue types and genetic disorders. This removes the lengthy process of negotiating individual cell line licences for Abzena and its customers.

The positive impact for customers will be a more streamlined development of specialised bioassays. It will be able to provide faster, more comprehensive and more efficient functional characterisation, lead selection and potency assay development for its customers’ novel biologic drug candidates.

Dr. Campbell Bunce, SVP, Scientific Operations, commented:

“Securing access to this cell bank will be a major benefit to both us and our customers. We will be able to offer broader capabilities for evaluating and testing our customers’ drug candidates to help advance the next generation of biopharmaceuticals.”

-Ends-

About Abzena

Abzena provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term ‘ABZENA Inside’ is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ‘ABZENA Inside’ products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, and Bristol, Pennsylvania:

  • Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development
  • Protein engineering to create humanized antibodies and deimmunised therapeutic proteins
  • Cell line development for the manufacture of recombinant proteins and antibodies
  • Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies
  • Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates
  • Proprietary site-specific conjugation technologies and novel payloads for ADC development
  • GMP manufacturer of ADC linkers, payloads & combined linker-payloads
  • GMP analytical services for biopharmaceutical manufacturing projects

For more information, visit www.abzena.com

Press Information


Published by
Hossam Abdel-Kader
+43 1 9582319
e-mail
http://www.pr-inside.com/


# 477 Words
Related Articles
More From The Author
Conditions for sale of Riksbank certificates
AUCTION DATE:MAR 13, 2018START DATE:MAR 14, 2018MATURITY DATE:MAR 21, 2018NOMINAL AMOUNT:433.7 BLNFIXED RATE:-0.50 % ALL MONETARY [..]
Norsk Hydro: Preliminary findings from internal task [..]
The internal expert task force established to review the Alunorte alumina refinery after the flooding in February has reported preliminary [..]
Sampo's Annual Report 2017 has been published
SAMPO PLC                 ANNUAL FINANCIAL REPORT       13 March 2018 at 9:30 am Sampo's Annual Report [..]
Clint Ford & Associates: Apartment Living Delivers [..]
A flat real estate market with even more apartments in the construction pipeline has forced real estate marketers to get [..]
General Electric files DEF 14A
FAIRFIELD, Conn., March 13, 2018 (GLOBE NEWSWIRE) -- Company General Electric CompanyISIN US3696041033Symbol London: GEC | [..]
 
More From Business
Hurricane Damages Creating Extraordinary Demand for Heavy [..]
The effects of Hurricane Florence have been wide and far reaching, with 37 deaths and billions of dollars in damages [..]
Over 2,900 Took Part in 'In Style [..]
HONG KONG, Sept 21, 2018 - (ACN Newswire) - Major events under the "In Style, Hong Kong" mega promotion in [..]
RetailEX ASEAN 2018 Returns Bigger and Better
Brand-new zones, content rich conferences and cutting-edge retail technology innovation and solutions featured during the three-day [..]
Singapore's Senior Minister of State for Trade [..]
SINGAPORE, Sept 21, 2018 - (ACN Newswire) - Asian Downstream Summit is the anchor oil and gas event during Singapore [..]
Vanwise and Carwise Group Scoop Dealer Award
Vanwise & Carwise Group has won the prestigious award by CarGurus as ‘Top Rated Dealer 2018’ ● Dealer scoops prestigious [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.